康希诺生物

2026

01

PCV24 received clinical trial approval
02

MCV4 expanded age indication to include individuals up to age 6
03

MCV4 and PCV13i manufacturing site received Malaysia NPRA PIC/S GMP Certificate
04

DTcP Infant vaccine Tripecia® obtained NDA approval

2025

01

MCV4 has been granted Halal Decree in Indonesia
02

Signed agreement with business partner from Saudi Arabia to commercialize MCV4
03

Signed an exclusive commercialization agreement with Grand Life Science Group for adsorbed tetanus vaccine
04

Application for registration of Absorbed Tetanus Vaccine
05

The DTcP Infant vaccine obtained priority review by NMPA
06

DTcP-Hib-MCV4 combined vaccine approved for clinical trials
07

Inhaled TB Booster Phase I clinical trial initiated in Indonesia
08

iPneucia® obtained NDA approval and officially launched
09

Launched first-in-class Three-Component LNP Delivery System
10

"Best ESG Employer of the Year" by Aon China for four consecutive years

2024

01

VLP-Polio received further funding from the Bill & Melinda Gates Foundation, and initiated clinical trial in Australia (Phase I) and Indonesia (Phase I / II)
02

Obtained the Acceptance Notice of drug registration applications for the PCV13i、DTcP Infant
03

Initiated Phase Ⅲ clinical trial for Absorbed Tetanus Vaccine
04

Initiated phase Ⅱ/Ⅲ clinical trial for the Tdcp Adolescent and Adult
05

Initiated Phase I clinical trial for the Hib Vaccine
06

Received positive results of Phase I clinical trials for the PBPV
07

MCV4 received the drug registration certificate granted in Indonesia
08

Obtained the Acceptance Notice of supplemental application to expand MCV4's applicable population to children aged from 3 months to 6 years old (83 months)
09

Collaborate with the National Institutes of Biotechnology Malaysia to develop the multivalent influenza mRNA vaccine

2023

01

The Tdcp adolescent and adult vaccine, recombinant zoster vaccine (IM & IH), and adsorbed tetanus vaccine have obtained clinical trial approvals in China or overseas and entered Phase I clinical trials
02

Menhycia® initiated age-indication expansion clinical trials
03

DTcP Infant vaccine entered Phase III clinical trial
04

The Recombinant Novel Coronavirus mRNA vaccine has received clinical trial approval; the inhaled Recombinant Novel Coronavirus XBB.1.5 variant vaccine included for emergency use
05

Initiated Phase Ib clinical trial for the global innovative vaccine PBPV
06

Grant Agreement with the Gates Foundation for VLP-Polio

2022

01

The Recombinant Novel Coronavirus vaccine Convidecia® was approved as heterologous booster in China
02

The WHO granted the Emergency Use Listing for the Recombinant Novel Coronavirus vaccine
03

The Shanghai R&D center & Phase I of the mRNA Manufacturing Facility completed

2021

01

The Recombinant Novel Coronavirus Vaccine Convidecia® received approval in over 10 countries
02

Menphecia® approved in China
03

Menhycia® approved in China
04

The COVID-19 Industrial Site has obtained the EU GMP certification
05

Convidecia Air® entered clinical research
06

Shanghai mRNA Manufacturing Facility started construction

2020

01

Listed on the Sci-Tech Innovation Board of SSE
02

Completed Convidecia® Phase II clinical trial, and launched multi-center Phase III clinical trials
03

Broad-spectrum pneumococcal protein vaccine, 13-valent Pneumococcal Polysaccharide Conjugate Vaccine entered clinical trials

2019

2018

2017

2016

2015

01

Pilot facility passed European QP inspection
02

Obtained CTA approvals of MCV2 & MCV4
03

Recognized as a talent cultivation cooperation development base of Nankai University
04

Recognized as a teaching practice base for master's degree students in the pharmacy program at Peking University

2014

2013

01

Filed CTA for MCV2 & MCV4
02

Recognized as a national high-tech enterprise
03

The Tianjin Respiratory Bacteria Recombination and Conjugate Vaccine Enterprise Key Laboratory has been established

2012

2011

2009